Saturday, 12 December 2009

Audit Scotland Warns of Pressures on the NHS Scotland Budget - Low Dose Naltrexone (LDN) Savings Cannot Be Ignored

And so it goes on, yet another reason why the 4000%+ higher price of currently used auto-immune and cancer treatments vs Low Dose Naltrexone (LDN) cannot be ignored any longer. The potential billions of pounds in savings here make the millions required for LDN clinical trials a sound investment for the NHS in Scotland and the UK as a whole.

No comments:

Post a Comment